$ATNM Venetoclax plus decitabine or azacitidine showed tolerable safety and favorable ORR 67% vs Actimab-A plus Venetoclax 86% ORR.. $rhhby $jnj $bmy $mrk $pfe $abbv $amgn $gild $sny $gsk $vrtx $sgen $bmrn $halo $tgtx $tril #Pennystocks @genentech $aveo